VC Fund Investments
Therapeutics firm Bugworks Research raises $18-M from Lightrock India, others
Bengaluru-based clinical stage multi-indication therapeutics company Bugworks Research has raised USD 18 million in a Series B1 round led by Lightrock India, with participation from existing investors The University of Tokyo Edge Capital (UTEC) Japan, Global Brain Corporation in Japan, 3oneCapital India, Acquipharma Holdings S.A, I.M Holdings B.V. and Featherlite Group India. Kiran Mazumdar-Shaw, CMD - Biocon, also participated in the round. The round will support the clinical development of BWC0977, a novel broad spectrum antibacterial agent available in both IV and oral forms, and the pre-clinical development of the company's adenosine immuno-oncology asset.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
